Advertisement

Topics

Press Release: Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia(R) in untreated adult ALK+ NSCLC patients

01:47 EDT 23 Sep 2016 | FinanzNachrichten

Novartis International AG / Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia(R) in untreated adult ALK+ NSCLC patients . Processed and transmitted by Nasdaq...

Original Article: Press Release: Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia(R) in untreated adult ALK+ NSCLC patients

NEXT ARTICLE

More From BioPortfolio on "Press Release: Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia(R) in untreated adult ALK+ NSCLC patients"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...